Future studies are needed to examine temporal patterns of epigenetic changes in AD, the mechanisms underlying epigenetic aberrations in AD, and whether inhibiting Smyd3 to restore NMDARs can ameliorate tau hyperphosphorylation and slow down cognitive decline. This evidence concerns the gene MAPT and Alzheimer disease.